These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29260621)

  • 61. Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein.
    Sasakawa H; Sakata E; Yamaguchi Y; Masuda M; Mori T; Kurimoto E; Iguchi T; Hisanaga S; Iwatsubo T; Hasegawa M; Kato K
    Biochem Biophys Res Commun; 2007 Nov; 363(3):795-9. PubMed ID: 17904099
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson's disease.
    Brys I; Bobela W; Schneider BL; Aebischer P; Fuentes R
    Int J Neurosci; 2017 Jan; 127(1):28-36. PubMed ID: 26856727
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Viral vectors, animal models and new therapies for Parkinson's disease.
    Schneider B; Zufferey R; Aebischer P
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S169-71. PubMed ID: 18585946
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Autoimmunity in Parkinson's disease.
    Pouplard A; Emile J
    Adv Neurol; 1984; 40():307-13. PubMed ID: 6695608
    [No Abstract]   [Full Text] [Related]  

  • 65. Successful GPi stimulation in genetic Parkinson's disease caused by mosaicism of alpha-synuclein gene duplication: first description.
    Perandones C; Aráoz Olivos N; Raina GB; Pellene LA; Giugni JC; Calvo DS; Radrizzani M; Piedimonte F; Micheli FE
    J Neurol; 2015 Jan; 262(1):222-3. PubMed ID: 25408368
    [No Abstract]   [Full Text] [Related]  

  • 66. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
    Zhang QS; Heng Y; Yuan YH; Chen NH
    Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.
    Brudek T; Winge K; Folke J; Christensen S; Fog K; Pakkenberg B; Pedersen LØ
    Mol Neurodegener; 2017 Jun; 12(1):44. PubMed ID: 28592329
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ovarian carcinoma therapy with monoclonal antibodies.
    Canevari S; Miotti S; Bottero F; Valota O; Colnaghi MI
    Hybridoma; 1993 Oct; 12(5):501-7. PubMed ID: 8300122
    [No Abstract]   [Full Text] [Related]  

  • 69. Genetic models of Parkinson's disease: mechanisms and therapies.
    Whitworth AJ; Pallanck LJ
    SEB Exp Biol Ser; 2008; 60():93-113. PubMed ID: 18309789
    [No Abstract]   [Full Text] [Related]  

  • 70. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Selective expression of α-synuclein-immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon.
    Sharrad DF; de Vries E; Brookes SJ
    J Comp Neurol; 2013 Feb; 521(3):657-76. PubMed ID: 22821666
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biologic Therapies of Immunologic Diseases.
    Chipps BE; Peters SP
    Immunol Allergy Clin North Am; 2017 May; 37(2):xvii-xviii. PubMed ID: 28366489
    [No Abstract]   [Full Text] [Related]  

  • 73. Parkinson's vaccine on trial.
    Pilcher H
    Lancet Neurol; 2005 Aug; 4(8):458-9. PubMed ID: 16086492
    [No Abstract]   [Full Text] [Related]  

  • 74. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 75. α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology.
    Christiansen JR; Olesen MN; Otzen DE; Romero-Ramos M; Sanchez-Guajardo V
    J Neuroinflammation; 2016 Apr; 13(1):74. PubMed ID: 27055651
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Monoclonal Antibodies in Neurodegenerative Disease May Work, But They Don't Help: A Perspective from Physicians.
    Richard E; Bloem BR
    J Parkinsons Dis; 2022; 12(8):2289-2291. PubMed ID: 36442210
    [No Abstract]   [Full Text] [Related]  

  • 78. Targeting α-Synuclein: A Further Viewpoint.
    Lang AE
    Mov Disord; 2023 Apr; 38(4):715-716. PubMed ID: 37061882
    [No Abstract]   [Full Text] [Related]  

  • 79. Monoclonal Antibody Therapy in Parkinson's Disease - The End?
    Whone A
    N Engl J Med; 2022 Aug; 387(5):466-467. PubMed ID: 35921458
    [No Abstract]   [Full Text] [Related]  

  • 80. This is NOT the End for Immunotherapy in Parkinson's Disease - A Perspective from Early Drug Development Scientists.
    Brundin P; Svoboda H; Bonni A; Pagano G
    J Parkinsons Dis; 2022; 12(8):2293-2296. PubMed ID: 36404558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.